Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flumatinib vs Imatinib in Newly Diagnosed CML-CP
NCT05367765Phase 4Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Apr 2022
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Flumatinib in chronic myeloid leukemia (CML) (2 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoint: Major Molecular Response Rate at 12 months. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
Flumatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT05367765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05367765.